10/570734

14720 REC'E VILLE O G MAR 2006' Docket No. 4126-4037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	t(s): Ariadna Fernandez Donis, Ernes Rodríguez, Sonia Varon Colome Andrés Francesch Solloso, José- Fernando Albericio Palomera	r, Carmen Cuevas N	
Carial Na	. ТЪ А	Group Art Unit:	TBA
Serial No.	.: TBA	Examiner:	TBA
Filed:	HEREWITH		
For:	NEW ANTITUMORAL COMPOUND	S	
	INFORMATION DISCL	OSURE STATEM	IENT
P.O. Box	ioner for Patents		
Attn: DO/	/EO/US		
Sir:	•		
	This Information Disclosure Stater	nent is filed in acco	rdance with 37 C.F.R.
§§1.56, 1.9	.97 and 1.98. The items listed on Form	PTO-1449, a copy o	of which is enclosed, are
made of re	ecord to assist the Patent and Trademark	Office in its exami	ination of this application.
The Exam	niner is respectfully requested to fully co	onsider the items and	d to independently ascertain
their teach	ning.		
_	For each of the following items listed on not in the English language, an English thereof or a concise explanation of the	language translatio	n of that item or a portion
	4		
	For each of the following items listed on not in the English language, a concise eincorporated in the specification of the	explanation of the re	elevance of that item is
	Any copy of the items listed on the enc 1449B that is not enclosed with this Inf cited by or submitted to the Patent and filed on	ormation Disclosur	e Statement was previously

4.	\boxtimes	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:				
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits.			
5.		sino in p Allo	fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement se it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified aragraph 4 above but before the mailing date of a final action or a Notice of towance (where there has been no prior final action), and is accompanied by one of certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.			
6.		it is para	being filed in compliance with 37 C.F.R. §1.17(p) for this Information Disclosure Statement since being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in agraph 4 above but before the mailing date of a final action or a notice of wance (where there has been no prior final action):			
			A check in the amount of \$180.00 is enclosed in payment of the fee.			
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.			
7.		it is	be is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final on or a notice of allowance, whichever comes first, but before payment of the issue and is accompanied by:			
		a.	one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and			
		b.	the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.			
8.		This	s Information Disclosure Statement is being filed in compliance with:			
		a.	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);			
		b.	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).			

10/570734 Docket No. 4126-4037

Serial No. TBA The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 c. IAP20 Rec'd PCT/PTO 0 6 MAR 2006 below. 9. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 10. This document is accompanied by \(\sqrt{\operation} \) a Search Report \(\sqrt{\operation} \) Communication which was cited in a corresponding | PCT or | Foreign counterpart application 11. A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p). Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED. \times The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4126-4037. Respectfully submitted, MORGAN & FINNEGAN, L.L.P. Dated: March 6, 2006 By: Kenneth H. Sonnenfeld // Michael A. Registration No. 33,285 // 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

INFORM		ORM PTO-1449A ON DISCLOSURE CITA	ATION 4126- Appli Ariad Pilar I Marcl Jimén Palon	cant: na Fernandez Do López Rodríguez nante, Ángel Lóp ez Garcia, Mirian nera	, Sonia Var ez Macia, <i>I</i>	Giralt Lle con Colon Andrés Fr pósito, an	edó, Carolina Graciner, Carmen Cueva ancesch Solloso, Jo dd Fernando Alberia	a Cantador, s osé-Carlos
-			Herev	Date: vith		Group A	Art Unit:	
		U.S. P	ATENT / PUBL	ICATION DOC	CUMENTS			
Examiner Initial		Patent/Publication Num	ber Publica	tion/Issue Date		Na	me	Filing Date
		_						
. × . /		× =	FOREIGN PAT	ENT DOCUME	ENTS		*	
Examiner Initial		Patent Number	Publication Date	Countr	y	Copy Filed	Translat	ion
	1.	WO 01/58934 A2	16 Aug. 2001	PCT		☐ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A
	2.	WO 03/033012 A1	24 Apr. 2003	PCT		☐ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A
	3.	WO 2004/035613 A2	29 Apr. 2004	PCT		☐ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A
	4.					☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A
	5.				ı	☐ Yes	☐ Yes ☐ No ☐ A	bstract N/A
	6.					☐ Yes	☐ Yes ☐ No ☐ A	bstract _N/A
Examiner				Date Considere				
EXAMINER:	Draw	if reference considered, whether or line through citation if not in confo e copy of this form with next comm	rmance and not consi	dered.	§609.			

Page 1 of 1

FORM PTO-1449B

INFORMATION DISCLOSURE CITATION

Attorney Docket: 4126-4037	Serial N TBA	lo. 10	5	70	7	3	4
Applicant:							

Applicant:
Ariadna Fernandez Donis, Ernest Giralt Lledó, Carolina Gracia
Cantador, Pilar López Rodríguez, Sonia Varon Colomer, Carmen Cuevas
Marchante, Ángel López Macia, Andrés Francesch Solloso, José-Carlos
Jiménez Garcia, Miriam Royo Expósito, and Fernando Albericio
Palomera

Filing Date:
Group Art Unit:
Herewith
TBA

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	1.	Hamann et al., "Kahalalides: Bioactive Peptides From A Marine Mollusk <i>Elysia Rufescens</i> And Its Algal Diet Bryopsis sp.," <u>J. Org. Chem.</u> , Vol. 61, pgs. 6594-6600, 1996.
	2.	López-Macià et al., "Synthesis And Structure Determination Of Kahalalide F," <u>J. Am. Chem. Soc.</u> , Vol. 123, No. 46, pgs. 11398-11401, 2001.
<u> </u>	3.	
	4.	
	5.	
	6.	
	7.	
	8.	
	9.	
	10.	
	11.	·
	12.	
	13.	
	14.	
***************************************	15.	
	16.	
	17.	
	18.	
	19.	
	20.	

Examiner	Date	
Signature	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.